NUOTQ
Nuo Therapeutics, Inc.OTCPK - Current
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 22, 7:57 AM
    • In a regulatory filing, Nuo Therapeutics (OTCPK:NUOTQ) reports that the PACE study assessing the Bright Cell Technology failed to demonstrate a treatment effect versus placebo in four co-primary endpoints. There were also no significant improvements quality-of-life secondary endpoints nor correlations with magnetic resonance outcomes and peak walking time.
    • A post-hoc analysis did show that ALDH bright cells were associated with an increase in the number of collateral arteries in participants with completely occluded femoral arteries.
    • The company says its is "unclear" whether the Bright Cell technology can or should be further developed.
    | Tue, Nov. 22, 7:57 AM
  • Nov. 6, 2014, 11:11 AM
    • Cytomedix (OTCQX:CMXI -1.4%) will report Q3 results on November 13 after the close. The conference call will begin the next day, November 14, at 8:00 am ET.
    | Nov. 6, 2014, 11:11 AM